[ad_1]
Clive Richardson, chief executive of Akari Therapeutics PLC (NASDAQ: AKTX), presents the activity at Proactive London and describes some of his work in the field of acute and chronic inflammation.
Speaking of their protein, Nomacopan, he explains that it is currently undergoing clinical evaluation in four indications, including a serious skin and vesicle disease and a threatening eye disease.
Source link
